How Peptides Are Engineered to Last Longer

2026. 10. 05. ·3 perc olvasás · Utoljára ellenőrizve 2026. 08. 29.

Native peptides are, as a class, extremely short-lived. GLP-1 survives about two minutes in circulation; GHRH not much longer. Yet a large part of the modern research-peptide catalog consists of analogues with half-lives measured in days. The gap is closed by a small, well-defined set of chemical strategies, and recognising them makes an unfamiliar peptide’s structure readable.

The two problems to solve

A peptide disappears from circulation by two independent routes, and a modification that solves one does nothing for the other:

1. Enzymatic degradation. Proteases cleave peptide bonds. Exopeptidases work from the ends; endopeptidases cut internally. Dipeptidyl peptidase-4 is the specific offender for the incretin and GHRH families, removing the first two N-terminal residues.
2. Renal clearance. The kidney filters molecules below roughly 60 kDa. Almost every peptide is far below that, so even a protease-proof peptide is filtered out within hours.

Strategies against enzymes

Non-proteinogenic residues

Aib (α-aminoisobutyric acid) is the most common. Two methyl groups on the alpha carbon add steric bulk that DPP-4 cannot accommodate, and they restrict backbone rotation, which stabilises helical structure. Semaglutide, tirzepatide and many others use it at the DPP-4 site.

D-amino acids

Proteases evolved to recognise L-residues. Substituting a D-enantiomer at a cleavage site makes the bond invisible to the enzyme. Ipamorelin uses D-2-Nal and D-Phe; Melanotan II uses D-Phe.

Terminal capping

N-terminal acetylation removes the free amine that aminopeptidases require. C-terminal amidation removes the free carboxylate that carboxypeptidases require. Many short peptides carry both — the -NH2 at the end of a sequence is this modification.

Cyclisation

A ring has no ends for exopeptidases to work from, and the constrained backbone is harder for endopeptidases to fit into an active site. Melanotan II’s lactam bridge does this.

N-terminal acylation

Attaching a group to the N-terminus can sterically block a cleavage site without changing the sequence. Tesamorelin’s trans-3-hexenoyl group is exactly this.

Strategies against renal clearance

Fatty-acid acylation

The dominant approach in modern long-acting peptides. A fatty diacid — typically C16 to C20 — is attached to a lysine side chain through a hydrophilic spacer, usually γ-glutamic acid plus AEEA units.

The fatty acid binds reversibly to serum albumin, which is large enough to escape filtration and long-lived. The peptide is effectively parked on a carrier and released slowly. The spacer’s job is to hold the lipid far enough away that receptor binding still works.

This single strategy is responsible for most of the week-long half-lives in the catalog.

PEGylation

Attaching polyethylene glycol chains increases hydrodynamic radius directly. Effective, but bulky, and it can interfere with receptor binding — which is why albumin binding largely displaced it for peptides.

Reading a structure

Once the vocabulary is familiar, a sequence tells you what it was designed to survive:

Our guide to reading peptide sequences covers the notation itself, and the synthesis article covers how these modifications are actually made.

All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.